Figure 6.
A schematic illustration of the mechanism of KDM4B inhibition-mediated immunosuppression. KDM4B activity inactivates KDM1A and allows for active transcription of pro-inflammatory cytokines while KDM4B inhibition allows for active demethylation by KDM1A, reducing pro-inflammatory cytokine production.